medigraphic.com

2016, Número 4

<< Anterior Siguiente >>

Rev Hematol Mex 2016; 17 (4)


Trombocitopenia inmunitaria primaria

Tamayo-Chuc DU

Idioma: Español
Referencias bibliográficas: 81
Paginas: 239-255
Archivo PDF: 612.99 Kb.


RESUMEN

La trombocitopenia inmunitaria primaria (anteriormente conocida como púrpura trombocitopénica idiopática y posteriormente como púrpura trombocitopénica inmunitaria) es una enfermedad autoinmunitaria en la que hay anticuerpos contra antígenos de superficie plaquetaria, lo que disminuye el conteo plaquetario y causa erupciones típicas (púrpura) y susceptibilidad al sangrado. Se describió desde hace más de cuatro siglos. A través de la historia, sus mecanismos fisiopatológicos de tipo inmunológico han permitido revelar sus características. En esta revisión bibliográfica describimos las opciones de tratamiento para proporcionar herramientas para la individualización del mismo. Asimismo, considerar las condiciones subyacentes de manera crítica es parte esencial para la toma de decisiones acerca de las líneas de tratamiento, que están muy bien definidas en la actualidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol 2011;153:437-450.

  2. Enersen, OD. Werlhof’s Disease [Sitio en Internet]. Oslo: Whonamedit? [actualizado: 2015; consultado: 2015 Abr 18]. Disponible en: http://www.whonamedit.com/synd. cfm/3349.html

  3. Liebman, HA. Immune thrombocytopenia (ITP): an historical perspective. Hematology Am Soc Hematol Educ Program 2008:205.

  4. Wintrobe MM, Cartwright GE, Palmer JG, et al. Effect of corticotrophin and cortisone on the blood in various disorders in man. AMA Arch Intern Med 1951;88:310-336.

  5. Harrington WJ, Minnich V, Hollingsworth JW. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1-10.

  6. Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-1231.

  7. Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991;77:1884-1893.

  8. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27:99-103.

  9. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114:891-898.

  10. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med 2011;365:734-741.

  11. Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85:174-180.

  12. Watts RG. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the children’s hospital of Alabama. Clin Pediatr (Phila) 2004;43:691-702.

  13. Treutiger I, Rajantie J, Zeller B, et al. Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity? Arch Dis Child 2007;92:704-707.

  14. Ou CY, Hsieh KS, Chiou YH, et al. A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur. Acta Paediatr Taiwan 2006;47:226-231.

  15. Nourse, JP. The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagul Fibrinolysis 2012;23:45-50.

  16. Seymour LA, et al. The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue Antigens 2014;83:154-160.

  17. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.

  18. Stevens W, Koene H, Zwaginga JJ, et al. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med 2006;64:356-363.

  19. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-2251.

  20. Regan C, Shutter J. Amgem to Discuss Romiplostim BLA [Sitio en Internet]. EE.UU: Drugs.com, 2008 Mar 12 [actualizado: 2008 Ago 22; consultado: 2015 Abr 22]. Disponible en: http://www.drugs.com/nda/romiplostim_ 080312.html

  21. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009;145:235-244.

  22. Anoop P. Immune thrombocytopenic purpura: historical perspective, current status, recent advances and future directions. Indian Pediatr 2012;49:811-818.

  23. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003;17:69-80.

  24. Kiefel V, Santoso S, Weisheit M, et al. Monoclonal antibody– specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987;70:1722-1726.

  25. Woods VL, Oh EH, Mason D, McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood 1984;63:368-375.

  26. Schwartz RS. Immune thrombocytopenic purpura—from agony to agonist. N Engl J Med 2007;357:2299-2301.

  27. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007;136:309-314.

  28. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-1124.

  29. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008;112:1325-1328.

  30. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991;78:2619-2625.

  31. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-1150.

  32. Ghanima W, Holme PA, Tjønnfjord GE. Immunologisk trombocytopeni–patofysiologi og behandling. Tidsskr Nor Laegeforen 2010;130:2120-2123.

  33. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004

  34. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determinate its safety and efficacy in children with immune thrombocytopenia. Blood 2011;118:28-36.

  35. Houwerzijil EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103:500- 506.

  36. Fung MK, Grossman BJ, Hillyer CD, et al. AABB Technical Manual. 18ª ed. Bethesda: AABB Press, 2014.

  37. Webert KE, Mittal R, Sigouin C, et al. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003;102:4306-4311.

  38. Mais DD. ASCP quick compendium of clinical pathology. 3ª ed. Chicago: ASCP Press, 2014.

  39. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425-442.

  40. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel. Ann Intern Med 1997;126:319-326.

  41. Liesner RJ, Machin SJ. ABC of clinical haematology. Platelet disorders. BMJ 1997 Mar;314:809-812.

  42. Anoop P. Decision to perform bone marrow aspiration in immune thrombocytopenic purpura must be based on evidence. Pediatr Hematol Oncol 2008;25:91-92.

  43. Sandoval C, Visintainer P, Ozkaynak MF, et al. Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. Pediatr Blood Cancer 2004;42:109-112.

  44. Naithani R, Kumar R, Mahapatra M, et al. Is it safe to avoid bone marrow examination in suspected ITP? Pediatr Hematol Oncol 2007;24:205-207.

  45. Ron-Guerrero CS, Barrera-Chairez E, Ron-Magaña AL, et al. Trombocitopenia persistente parecida a púrpura trombocitopénica inmune asociada al dengue hemorrágico: informe de tres casos. Rev Hematol Mex 2013;14:86-90.

  46. Redeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.

  47. De Mattia D, Del Vecchio GC, Russo G, et al. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol 2010;123:96- 109.

  48. Blanchette V. Childhood chronic immune thrombocytopenic purpura (ITP). Blood Rev 2002;16:23-26.

  49. Anoop P. Variations in the treatment threshold for immune thrombocytopenic purpura. Pediatr Blood Cancer 2009;52:429-431.

  50. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.

  51. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-596.

  52. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.

  53. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.

  54. Hilgartner MW, Lanzkowsky P, Smith CH. The use of azathioprine in refractory idiopathic thromobocytopenic purpura in children. Acta Paediatr Scand 1970;59:409-415.

  55. Choudhary DR, Naithani R, Mahapatra M, et al. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica 2008;93:61-63.

  56. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003;70:353-357.

  57. Damodar S, Viswabandya A, George B, et al. Dapsone for chronic idiopathic thrombocytopenic purpura in chil dren and adults: a report on 90 patients. Eur J Haematol 2005;75:328-331.

  58. Marwaha RK, Singh RP, Garewal G, et al. Danazol therapy in immune thrombocytopenic purpura. Pediatr Hematol Oncol 1990;7:193-198.

  59. Imbach P, Kühne T, Müller D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006;46:351-356.

  60. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Prevention and therapy of bacterial infections for children with asplenia or hyposplenia. Paediatr Child Health 1999;4:417-421.

  61. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.

  62. Imbach P. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. Swiss Med Wkly 2012;142:13593.

  63. Idiopathic thrombocytopenic purpura (ITP) [Sitio en Internet]. EE.UU: Mayo Clinic; 2014 Dic 10 [consultado: 2015 May 18]. Disponible en: http://www.mayoclinic. org/diseases-conditions/idiopathic-thrombocytopenicpurpura/ basics/definition/con-20034239

  64. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-648.

  65. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247.

  66. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-1681.

  67. Kutter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-1899.

  68. Hawkins T, Sood A. FDA Approves Nplate(TM) for Long- Term Treatment of Adult Chronic ITP. [Comunicado en Internet]. EE.UU: AMGEN; 2008 Ago 22 [consultado: 2015 May 18]. Disponible en: http://www.amgen.com/media/ media_pr_detail.jsp?year=2008&releaseID=1189823

  69. Liang Y, Zhang L, Gao Y, et al. Rituximab for children with immune thrombocytopenia: a systemic review. PLoS One 2012;7:36698.

  70. GlaxoSmithKline. FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder. [Comunicado en Internet]. EE.UU: GlaxoSmithKline, 2008 Nov 20 [consultado: 2015 May 18]. Disponible en: http://web.archive. org/web/20101227031913/http://www.gsk.com/media/ pressreleases/2008/2008_pressrelease_10127.htm

  71. George JN, Buchanan GR. Splenectomy and ITP. [Artículo en Internet]. EE.UU: ITP Support Association, 2004 Dic [consultado: 2015 May 18]. Disponible en: http://www.itpsupport. org.uk/american/%205.%20Splenectomy%20in%20ITP.pdf

  72. Minkov M. Critical issues concerning splenectomy for chronic idiopathic thrombocytopenic purpura in childhood. Pediatr Blood Cancer 2006;47:734-736.

  73. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009;113:1231-1240.

  74. Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol 1997;97:336-339.

  75. Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res 2014;306:103-124.

  76. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27:99-103.

  77. National Institute for Health and Care Excellence. Immune (idiopathic) thrombocytopenic purpura: rituximab [Guía de práctica clínica en Internet]. EE.UU: NICE, 2014 Oct [consultado: 2015 May 19]. Disponible en: https://www. nice.org.uk/advice/esuom35

  78. Salama A, Rieke M, Kiesewetter H, et al. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol 2009;88:11-15.

  79. Li X, Hou M. Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs 2008;13:237-257.

  80. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010;12:734-740.

  81. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154-3160.




2020     |     www.medigraphic.com